EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Targeting CD70 in cancer: Mechanisms of immune escape and translational opportunities

Akash Sabarwal, Saba Tabasum, Laxminarayan Rawat, Soumitro Pal

Clinical and Translational Discovery · 2025-12 · 5 (6)

DOI: 10.1002/ctd2.70095 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical and Translational Discovery, online erschienen am 30.10.2025. Verfasst von Akash Sabarwal und 3 weiteren Autor:innen. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 63 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Institutes of Health.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

CD70, a tightly regulated immune co‐stimulatory ligand under physiological conditions, becomes aberrantly and persistently overexpressed in a wide spectrum of malignancies, including renal cell carcinoma (RCC), glioblastoma and acute myeloid leukaemia. This tumour‐restricted expression pattern, coupled with its potent immunomodulatory effects, positions CD70 as a uniquely actionable target in modern oncology. Unlike classical immune checkpoints, CD70 contributes to immune escape by chronically engaging CD27, leading to T cell exhaustion, regulatory T cell (Treg) expansion and myeloid‐derived suppressor cell activation, collectively shaping a profoundly immunosuppressive tumour microenvironment. Mechanistically, CD70 expression is amplified by convergent oncogenic, inflammatory and hypoxic signals, most notably HIF‐2α stabilization in VHL‐deficient RCC, linking it to aggressive disease biology and poor prognosis. Notably, CD70 expression in tumours often coexists with dysregulation of receptor tyrosine kinase (RTK) pathways (e.g. MET, AXL) and immune checkpoint circuits (e.g. PD‐1/PD‐L1), supporting rationale combination therapies aimed at overcoming resistance and enhancing anti‐tumour immunity. A diverse array of CD70‐directed therapies, including antibody‐drug conjugates, CAR‐T and CAR‐NK cells, monoclonal antibodies and radiotheranostic agents, are advancing through preclinical and early clinical pipelines. Beyond therapeutic applications, CD70 also holds promise as a biomarker for tumour detection, patient stratification and response monitoring. This mini‐review synthesizes emerging insights into CD70‐driven immune evasion, highlights evolving therapeutic strategies and discusses the integration of CD70 targeting into next‐generation immunotherapy and precision oncology platforms. This review is novel in linking CD70‐mediated immune escape to oncogenic RTK signalling and in foregrounding recent translational advances and rational combination strategies that have not been comprehensively covered in prior reviews.

Förderung

  • National Institutes of Health

Zitieren

APA

Sabarwal, A., Tabasum, S., Rawat, L., & Pal, S. (2025). Targeting CD70 in cancer: Mechanisms of immune escape and translational opportunities. Clinical and Translational Discovery, 5(6). https://doi.org/10.1002/ctd2.70095

Vancouver

Sabarwal A, Tabasum S, Rawat L, Pal S. Targeting CD70 in cancer: Mechanisms of immune escape and translational opportunities. Clinical and Translational Discovery. 2025;5(6). doi:10.1002/ctd2.70095

BibTeX
@article{Sabarwal2025,
  author = {Sabarwal, Akash and Tabasum, Saba and Rawat, Laxminarayan and Pal, Soumitro},
  title = {Targeting CD70 in cancer: Mechanisms of immune escape and translational opportunities},
  journal = {Clinical and Translational Discovery},
  year = {2025},
  volume = {5},
  number = {6},
  doi = {10.1002/ctd2.70095}
}
Kostenlos starten →